Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review

• References

• 1 Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-391.
• 2 Collins PW, Chalmers E, Hart DP. et al. UK Haemophilia Centre Doctors. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia. 4th edition UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-170.
• 3 Morfini M, Haya S, Tagariello G. et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
• 4 DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007; 138: 305-315.
• 5 Gringeri A, Mantovani LG, Scalone L. et al. for the COCIS Study Group. Cost of care and quality of life for patients with haemophilia complicated by inhibitors: the COCIS Study. Blood 2003; 102: 2358-2363.
• 6 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in haemophilia patients with inhibitors. Semin Thromb Haemost 2013; 39: 772-778.
• 7 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in haemophilia. Blood 2014; 124: 3365-3372.
• 8 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 09: 418-435.
• 10 Brooker M. World Federation of Haemophilia. Registry of clotting factor concentrates. Ninth Edition, 2012. Facts and Figures. 2012 06. 1-19 Available at http://www.wfh.org Accessed on February 9, 2016.
• 9 Lee CA, Lillicrap D, Astermark J. Inhibitor development in haemophiliacs: the roles of genetic versus environmental factors. Semin Thromb Haemost 2006; 32 (Suppl. 02) 10-14.
• 11 Shapiro AD, Ragni MV, Lusher JM. et al. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with haemophilia B. Thromb Haemost 1996; 75: 30-35.
• 12 Parquet A, Laurian Y, Rothschild C. et al. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate. Thromb Haemost 1999; 82: 1247-1249.
• 13 Knobe KE, Sjörin E, Tengborn LI. et al. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey. Acta Paediatr 2002; 91: 910-914.
• 14 Shapiro AD, Di Paola J, Cohen A. et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe haemophilia B. Blood 2005; 105: 518-525.
• 15 Kreuz W, Auerswald G, Budde U. et al. and the GTH-PUP-Study Group. In: Scharrer I, Schramm W. eds. Inhibitor development in previously untreated patients (PUPs) with haemophilia A and B. A prospective multicentre study of the German, Swiss and Austrian Society of Thrombosis and Haemostasis Research (GTH). 35th. Haemophilia Symposium, Hamburg. 2004. Heidelberg: Springer Verlag; 2005: 34-37.
• 16 Monahan PE, Liesner R, Sullivan ST. et al. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B. Haemophilia 2010; 16: 460-468.
• 17 Fischer K, Lassila R, Peyvandi F. et al. on behalf of the EUHASS participants. Inhibitor development in haemophilia according to concentrate. Fouryear results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113: 968-975.
• 18 Ljung R, Petrini P, Tengborn L. et al. Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br J Haematol 2001; 113: 81-86.
• 19 Franchini M, Lippi G, Montagnana M. et al. Anaphylaxis in patients with congenital bleeding disorders and inhibitors. Blood Coagul Fibrinolysis 2009; 20: 225-229.
• 20 Chitlur M, Warrier I, Rajpurkar M. et al. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009; 15: 1027-1031.
• 21 Recht M, Pollmann H, Tagliaferri A. et al. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B. Haemophilia 2011; 17: 494-499.
• 22 Björkman S. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing. Haemophilia 2011; 17: 179-184.
• 23 Rocino A, Coppola A, Franchini M. et al. Principles of treatment and update of recommendations for management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion 2014; 12: 575-598.
• 24 Berntorp E, Gretenkort-Andersson N. Prophylaxis for haemophilia in the era of long-acting FVIII/ FIX products. Semin Thromb Haemost. 2016 42. in press.